Quarterly ResultMay 14, 2026, 04:10 PM
Serina Therapeutics Q1 Net Loss $6.9M; Advances Parkinson's Study
AI Summary
Serina Therapeutics reported a net loss of $6.9 million for the first quarter ended March 31, 2026, an increase from a $4.8 million net loss in Q1 2025. The company also provided key business updates, including the ongoing Phase 1b registrational clinical study of SER-252 for advanced Parkinson's disease, with TFL data from the SAD arm targeted for the first half of 2027. Additionally, Serina successfully closed a $21.2 million private placement financing in March and April 2026, significantly strengthening its balance sheet with cash and cash equivalents totaling $24.5 million as of March 31, 2026.
Key Highlights
- Net loss attributable to Serina: $(6.9) million for Q1 2026, up from $(4.8) million in Q1 2025.
- Basic and diluted net loss per share: $(0.58) for Q1 2026, compared to $(0.49) for Q1 2025.
- Operating expenses: $6.3 million for Q1 2026, up from $5.9 million in Q1 2025.
- Research and Development (R&D) expenses: $3.2 million for Q1 2026, compared to $3.0 million for Q1 2025.
- Closed $21.2 million private placement financing in March and April 2026.
- Cash and cash equivalents totaled $24.5 million as of March 31, 2026.
- Phase 1b registrational clinical study of SER-252 for Parkinson's disease is underway.
- TFL data from the SAD study arm of SER-252 targeted for first half of 2027.
Price Impact
More from SER